A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-10-18
Adverse events
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-10 (study day 195); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-20 (study day 205); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-22 (study day 299); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-13 (study day 321); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-29 (study day 367); relationship: N
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-22 (study day 452); relationship: not assessed
Data queries
No data queries.